Hong Kong scrambles for talent in battle for Nasdaq’s biotech crown

HONG KONG (Reuters) – When Hong Kong unveiled plans last year to encourage biotech companies to list in the city by loosening listing rules, the financial industry and investors cheered.

Powered by WPeMatico

Scroll to top